Back to User profile » Dr Faris Tamimi
Papers published by Dr Faris Tamimi:
Bridging Clinical Trials to Real-World Clinical Practice: TCHP Neoadjuvant Therapy Outcomes in HER2-Positive Breast Cancer
Sharaf B, Seif A, Bani Hani H, Alhasan M, Khader R, Al-Yag’oub M, Ghanem A, Bani Ata J, Ajlouni B, Jawarneh Q, Jaffal A, Tamimi F, Jehad S, Al-Abdallat H, Mahafdah O, Abdel-razeq H
Breast Cancer: Targets and Therapy 2026, 18:559555
Published Date: 9 April 2026
Enhancing Early Detection of Pancreatic Cancer in Genetically Predisposed Individuals: Integrating Advanced Imaging Modalities with Emerging Biomarkers and Liquid Biopsy
Abdel-Razeq R, Mansour A, Barbar M, Abu Shanap M, Sharaf B, Tamimi F, Mansour R, Muhanna A, Al-Othman Y, Hammad H, Shakhatreh M, Mahafdah S, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:511-523
Published Date: 30 August 2025
Escalation and De-Escalation Strategies for Endocrine Therapy in Early-Stage Breast Cancer
Al-Batsh T, Abdel-Razeq N, Al-Masri Y, El-Khatib O, Sharaf B, Tamimi F, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:97-111
Published Date: 13 March 2025
Dual Anti-HER2 Therapy Vs Trastuzumab Alone with Neoadjuvant Anthracycline and Taxane in HER2-Positive Early-Stage Breast Cancer: Real-World Insights
Sharaf B, Tamimi F, Al-Abdallat H, Khater S, Salama O, Zayed A, El Khatib O, Qaddoumi A, Horani M, AL-Masri Y, Asha W, Altalla’ B, Bani Hani H, Abdel-Razeq H
Biologics: Targets and Therapy 2025, 19:59-71
Published Date: 5 March 2025
Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country
Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, El Khatib O, Edaily S, Abunasser M, Tamimi F, Al-Masri YN, Al-Batsh TMW, Zayed A, Ghatasheh T, Radaideh T
ImmunoTargets and Therapy 2024, 13:501-512
Published Date: 29 September 2024
Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib
Sharaf B, Abu-Fares H, Tamimi F, Al-Sawajneh S, Salama O, Daoud R, Alhajahjeh A, Al-Lababidi S, Abdel-Razeq H
Breast Cancer: Targets and Therapy 2023, 15:541-548
Published Date: 28 July 2023
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer
Abdel-Razeq H, Abujamous L, Al-Azzam K, Abu-Fares H, Bani Hani H, Alkyam M, Sharaf B, Elemian S, Tamimi F, Abuhijla F, Edaily S, Salama O, Abdulelah H, Daoud R, Abubaker M, Al-Atary A
Breast Cancer: Targets and Therapy 2023, 15:1-10
Published Date: 13 January 2023
Patterns and Prevalence of BRCA1 and BRCA2 Germline Mutations Among Patients with Triple-Negative Breast Cancer: Regional Perspectives
Abdel-Razeq H, Tamimi F, Abujamous L, Edaily S, Abunasser M, Bater R, Salama O
Cancer Management and Research 2021, 13:4597-4604
Published Date: 9 June 2021